Korean J Transplant.  2022 Nov;36(Supple 1):S79. 10.4285/ATW2022.F-1967.

Mac-2 binding protein glycan isomer is new serum biomarker for assessing liver fibrosis: non-invasive method

• Minjuur B
• Chinburen J

• KMID: 2535595
• DOI: http://doi.org/10.4285/ATW2022.F-1967

Abstract

Background
Hepatitis B virus (HBV) and hepatitis C virus (HCV) hepatitis are common in Mongolia; therefore, above mentioned diseases related hepatocellular carcinoma (HCC) and end stage cirrhosis are serious concern of our country. Most patients with HCC, who undergo liver resection, have chronic liver disease. As a result of it, complications of liver resection are usual. For these reasons, we assess liver fibrosis via Mac-2 binding protein glycan isomer (M2BPGi) in order for diminishing the complications and planning of operation.
Methods
Two-hundred-twenty-six patient with HCC, who are subjected to liver resection, are participated to measure fibrosis in this study from 2015 to 2017. In order to assess fibrosis, M2BPGi are taken from patients before operation. The result of M2BPGi are compared with postoperation specimen by ISHAK.
Results
Although the number of specimens was small, M2BPGi tended to be very high at F4 stage in both HBsAg and Anti-HCV positive specimens. Compared to HBsAg positive, M2BPGi tended to be high in Anti-HCV positive specimens.
Conclusions
M2BPGi correlated with fibrosis stage in specimens gathered at the Mongolian Cancer Center and showed high discrimination ability in F3 / 4 in ROC analysis. M2BPGi is thought to be a useful biomarker in liver fibrosis. However, HBV tends to have a lower value than HCV, so careful attention to background disease is necessary for interpretation of result.